Clinical Trials

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT07346105 2026-01-16

Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies

Temporarily not available

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04360005 2025-12-05

Managed Access Programs for ABL001, Asciminib

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04745637 2025-11-18

Managed Access Programs for INC424, Ruxolitinib

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT05269771 2025-11-05

MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera

Myeloid

Polycythemia Vera

NCT05593185 2024-12-09

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05219266 2024-06-28

Managed Access Programs for PKC412, Midostaurin

Leukemia, Mast-Cell, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT03592576 2024-05-06

Expanded Access to Navitoclax

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT04518644 2023-04-28

Nilotinib, for Patients With CML-CP or CML-AP

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01592136 2018-02-06

Expanded Access Program of Ponatinib

Approved for marketing

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00905593 2012-07-18

ENACT

Approved for marketing

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00302016 2011-08-26

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia